Sorrento Therapeutics Inc
NASDAQ:SRNE
Sorrento Therapeutics Inc
Revenue
Sorrento Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sorrento Therapeutics Inc
NASDAQ:SRNE
|
Revenue
$62.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Sorrento Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
Sorrento Therapeutics Inc
Breakdown by Segments
Sorrento Therapeutics Inc
Total Revenue:
62.8m
USD
|
Product:
45m
USD
|
Scilex Pharmaceuticals Inc Product Sales:
38m
USD
|
Service:
17.8m
USD
|
Sorrento Therapeutics, Inc. Product Revenues:
7m
USD
|
Other Service Revenue:
6.2m
USD
|
Service Drug And Reagants:
3m
USD
|
Service Customized Reagents:
700k
USD
|
See Also
What is Sorrento Therapeutics Inc's Revenue?
Revenue
62.8m
USD
Based on the financial report for Dec 31, 2022, Sorrento Therapeutics Inc's Revenue amounts to 62.8m USD.
What is Sorrento Therapeutics Inc's Revenue growth rate?
Revenue CAGR 1Y
19%
Over the last year, the Revenue growth was 19%.